Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Purchases $15,540.00 in Stock

Anixa Biosciences, Inc. (NASDAQ:ANIX) Director Lewis H. Titterton, Jr. purchased 6,000 shares of Anixa Biosciences stock in a transaction that occurred on Tuesday, January 21st. The shares were purchased at an average cost of $2.59 per share, with a total value of $15,540.00. Following the transaction, the director now directly owns 928,334 shares of the company’s stock, valued at $2,404,385.06. This represents a 0.65 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link.

Anixa Biosciences Trading Down 3.4 %

Shares of ANIX stock opened at $2.82 on Friday. The stock has a market capitalization of $90.80 million, a P/E ratio of -7.23 and a beta of 0.90. The firm’s 50 day moving average is $2.76 and its 200 day moving average is $3.04. Anixa Biosciences, Inc. has a 12-month low of $2.07 and a 12-month high of $4.79.

Anixa Biosciences (NASDAQ:ANIX) last released its quarterly earnings results on Friday, January 10th. The company reported ($0.09) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.02. As a group, equities analysts predict that Anixa Biosciences, Inc. will post -0.46 earnings per share for the current year.

Institutional Investors Weigh In On Anixa Biosciences

Several hedge funds and other institutional investors have recently made changes to their positions in the business. Virtu Financial LLC purchased a new position in shares of Anixa Biosciences in the third quarter worth approximately $34,000. Westside Investment Management Inc. raised its position in Anixa Biosciences by 151.8% in the third quarter. Westside Investment Management Inc. now owns 35,000 shares of the company’s stock worth $110,000 after acquiring an additional 21,100 shares during the period. International Assets Investment Management LLC boosted its stake in shares of Anixa Biosciences by 170.0% during the 3rd quarter. International Assets Investment Management LLC now owns 37,800 shares of the company’s stock worth $1,190,000 after acquiring an additional 23,800 shares during the last quarter. Finally, Tyler Stone Wealth Management grew its position in shares of Anixa Biosciences by 100.0% during the 3rd quarter. Tyler Stone Wealth Management now owns 42,016 shares of the company’s stock valued at $132,000 after acquiring an additional 21,008 shares during the period. Hedge funds and other institutional investors own 29.13% of the company’s stock.

Analysts Set New Price Targets

A number of research firms have commented on ANIX. HC Wainwright reissued a “buy” rating and issued a $7.00 target price on shares of Anixa Biosciences in a report on Tuesday, November 19th. D. Boral Capital reissued a “buy” rating and issued a $10.00 target price on shares of Anixa Biosciences in a research report on Wednesday.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.